VRDN · Viridian Therapeutics, Inc.
$23.34
+4.34% last session
End-of-day data · close of 2026-10-26
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-8.5
Dividend yield
0.0%
Beta
1.10
Avg volume
2M
Employees
0K
Daily Change %
4.34%
5 Days Change
2.28%
10 Days Change
22.65%
30 Days Change
14.02%
60 Days Change
1.13%
Month to Day Change
22.91%
Year to Day Change
-25.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VRDN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-22
Latest call per bank · past 12 months
RBC Capital
Outperform$38.00
+62.8% vs priceWells Fargo
Overweight$31.00
+32.8% vs priceGoldman Sachs
Buy$31.00
+32.8% vs priceUBS
Buy$50.00
+114.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | RBC Capital | Maintains | Outperform | $36.00 → $38.00 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $35.00 → $36.00 |
| 2026-08-07 | Truist Securities | Maintains | Buy | $38.00 → $39.00 |
| 2026-06-30 | RBC Capital | Maintains | Outperform | $34.00 → $35.00 |
| 2026-06-30 | Truist Securities | Maintains | Buy | $35.00 → $38.00 |
| 2026-06-30 | Wedbush | Maintains | Outperform | $32.00 → $43.00 |
| 2026-06-30 | Needham | Maintains | Buy | $32.00 → $34.00 |
| 2026-06-29 | Wells Fargo | Upgrade | Equal-Weight → Overweight | $20.00 → $31.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 65 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 7.9% above the 50-day MA ($21.63).
- bullish: Price vs 200-day MA: Trading 6.5% above the 200-day MA ($21.92).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.60) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($13.30) and high ($33.78).
VRDN Price Chart
Loading chart for VRDN…
Fundamentals
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.